Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Diabetic Macular Edema/Diabetic Retinopathy | Unmet Need | Diabetic Macular Edema | US/FR/DE/UK | 2021

Login to access report north_east
Contact sales account_box

Diabetic macular edema (DME) represents the second-largest ophthalmology market for intravitreal anti-VEGF therapies, including Roche / Novartis’s Lucentis and Regeneron / Bayer’s market-leading Eylea. Because these therapies require regular injections to be effective, they present a major delivery burden that often impacts patient compliance. The corticosteroid implants Ozurdex (AbbVie) and Iluvien (Alimera Sciences) provide a longer duration of action between doses but are associated with side effects that relegate them to later-line treatment. Therefore, unmet need remains for therapies that provide strong efficacy for improving visual acuity with less-frequent dosing.

QUESTIONS ANSWERED

  • What are the key treatment drivers and goals for DME that influence ophthalmologists’ choice of therapies?
  • What drug attributes are key influences, which have limited impact, and which are hidden opportunities in the DME market?
  • How do ophthalmologists perceive the performance of current therapies on key treatment drivers and goals for DME?
  • What are the prevailing areas of market opportunity in the treatment of DME? Will emerging therapies, such as Novartis’s Beovu or Roche’s faricimab, fulfill these unmet needs?
  • What trade-offs are acceptable to U.S. and European ophthalmologists for a hypothetical DME drug?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European ophthalmologists fielded in February 2021

Key companies: Roche / Genentech, Regeneron / Bayer, Novartis, AbbVie (Allergan), Alimera Sciences, Kodiak Sciences

Key drugs: Lucentis, Eylea, Avastin, Ozurdex, Iluvien, Beovu, ranibizumab port delivery system, high-dose aflibercept, KSI-301, faricimab

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Muscular Dystrophy – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. The standard treatment for MD…
north_east
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…
north_east
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
north_east
Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
north_east
Report
Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or functional loss of melanocytes. Given its visible manifestations, the disease is associated with a substantial…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east